IBIO
iBio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Linked news
iBio has 5 disclosed suppliers and 12 disclosed customers in SEC filings.
SentenceThese licenses exist under two exclusive license agreements (the "AstralBio Licenses") with AstralBio granting us exclusive, worldwide licenses to develop, manufacture, commercialize and otherwise exploit, IBIO-600 and IBIO-610, which are our most advanced preclinical product candidates.
IBIO 10-Kaccession 0001420720-26-000020
SentenceWe engaged Chardan to act as our financial advisor in connection with the transactions summarized above and paid Chardan an aggregate fee equal to approximately $217,000 in connection with the transactions contemplated by the Inducement Agreement.
IBIO 10-Kaccession 0001558370-25-011888
SentenceWe outsource certain functions and supplies to third parties such as Lonza Sales AG, and Twist Bioscience Corporation.
IBIO 10-Kaccession 0001558370-25-011888
SentenceIn connection with the entry into the Collaboration Agreement and RTX-003 License Agreement, iBio also entered into a Stock Purchase Agreement ("Stock Purchase Agreement") with RubrYc whereby we purchased 1,909,563 shares of RubrYc's Series A-2 preferred stock ("Series A-2 Preferred") for $5,000,000 and acquired an additional 954,782 shares of RubrYc's Series A-2 Preferred.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceAs part of the collaboration, we granted an exclusive license to our AI-powered technology to identify and engineer four (4) targets for the treatment of obesity and cardiometabolic diseases, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug ("IND") application.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceIn fiscal year 2024, net cash provided by investing activities was $0.9 million, which primarily consisted of proceeds from the sale of intellectual property rights to Otsuka of $1 million and proceeds from the sale of fixed assets of $0.1 million, offset by the purchase of fixed assets of $0.2 million.
IBIO 10-Kaccession 0001558370-25-011888
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
SentenceOn May 17, 2024, iBio CDMO entered into a purchase and sale agreement (the "2024 Purchase and Sale Agreement") with The Board of Regents of the Texas A&M University System ("The Board of Regents") pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement with The Board of Regents, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015 (together with the Ground Lease Agreement, the "Ground Lease"), related to 21.401 acres in Brazos County, Texas (the "Land") and complete the sale to The Board of Regents of: (i) the buildings, parking areas, improvements, and fixtures situated on the Land (the "Improvements"); (ii) all iBio CDMO's right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the "Personal Property"); (iii) all iBio CDMO's rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the "Contracts"); and (iv) all iBio CDMO's rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the "Intangibles"; and together with the Ground Lease, Improvements and Personal Property, collectively, the "Property").
IBIO 10-Kaccession 0001558370-25-011888
SentenceClosed a public offering in August 2025 for a total gross proceeds of up to $100 million: The offering was led by Balyasny Asset Management, and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wave, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
IBIO 10-Kaccession 0001420720-26-000020
iBio, Inc.
0.75
Expected move
No implied move.